Small and ArQule.

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma Daiichi Sankyo Company, Small and ArQule, Inc. today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC trial of tivantinib . Tivantinib, an investigational selective inhibitor of MET, a receptor tyrosine kinase, is being evaluated for the treating patients diagnosed with hepatocellular carcinoma who have received one or two prior systemic anti-tumor therapies. The METIV-HCC trial is usually a randomized, double-blinded, controlled research of previously treated individuals with MET-high inoperable HCC who’ll receive placebo or tivantinib.


Apparently mindless survival strategies best for long-term success of genes Blindly copying what your parents did – no matter how stupid it may look – could be the best technique for the long-term success of your genes, according to analyze by the Universities of Bristol and Exeter. The findings of the scholarly study, released in Ecology Letters, display that evidently mindless survival strategies – such as the long-distance migration of several animals to breed at the place these were born – might not be as impractical because they appear. Using mathematical models, researchers compared the evolutionary success of straightforward copying strategies with that of even more dynamic approaches that focused on adapting to fresh information to make key life-style decisions.

Other entries from category "nutrition":

Random entries